Rare bleeding disorders and advances in gene therapy

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Rare bleeding disorders often manifest in childhood with potentially life-threatening bleeding.
• Hereditary coagulation factor deficiencies, including those of prothrombin, factor VII, and factor X, represent a significant challenge in hematology.
• Advances in gene editing technology present a promising avenue for the fundamental cure of these disorders.

Purpose of the Study:

• To review recent discoveries of mutations in prothrombin, factor VII, and factor X.
• To provide a comprehensive understanding of rare bleeding disorders essential for new treatment strategies.
• To introduce the current progress and challenges in the gene therapy of hereditary coagulation factor disorders.

Main Methods:

• Literature review of recently discovered mutations in prothrombin, factor VII, and factor X.
• Compilation and analysis of clinical and genetic features of these mutations.
• Review of current research and clinical trial data on gene therapy for coagulation factor disorders.

Main Results:

• Identification and characterization of novel mutations affecting prothrombin, factor VII, and factor X function.
• Detailed description of the clinical manifestations associated with these newly identified mutations.
• Overview of the current state of gene therapy, including successes and limitations.

Conclusions:

• Comprehension of rare bleeding disorder mutations is crucial for developing effective gene therapies.
• Gene therapy holds significant potential for curing hereditary coagulation factor disorders.
• Further research is needed to overcome obstacles and optimize gene therapy strategies for these rare diseases.